Project Mitigate

Ruprecht Karl University of Heidelberg, DE

University Medical Center Mannheim, Department of Clinical Radiology and Nuclear Medicine (IKRN)

Role and Contribution


Stefan Schönberg


Professor and Chairman of the Department of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Medical Faculty Mannheim – University of Heidelberg.

Professional Career
2002 Habilitation (Radiology), University of Heidelberg
2002 Associate Professor of Radiology, Section Chief MRI, Department of Clinical Radiology at the Ludwig-Maximilians University Munich
2004 Associate Chair of Clinical Operations, Department of Clinical Radiology at the Ludwig-Maximilians University Munich
Since 2007 Chairman, Department of Clinical Radiology and Nuclear Medicine, University Medical Centre Mannheim, Medical Faculty Mannheim – University of Heidelberg

2004 Visiting professorship in the field of magnetic resonance imaging at Stanford University, CA, USA
Since 2008 Director of the chair conference in German Radiology
Since 2008 Member of the Board of the Institute of Medical Technology (IMT)
2010 – 2013 Member of the European Institute for Biomedical Imaging Research (EIBIR) and Scientific Coordinator for medical imaging of Euro-BioImaging
Since 2012 Member of the International Society of Strategic Studies in Radiology (IS³R), since 2013 member of the executive board
Since 2013 MITIGATE Scientific Coordinator

Main research
Vascular and abdominal imaging
Functional magnetic resonance tomography
High-field magnetic resonance tomography
Oncologic imaging

Steffen Diehl


Prof. Dr. med. Steffen Diehl, senior consultant physician of the Department of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim leads the minimally-invasive-therapy section.

His main research interest includes abdominal, oncological and vascular imaging, especially in the field of magnetic resonance and computed tomography angiography.

In the MITIGATE project he is responsible for the investigation of new minimally-invasive treatment concepts for gastrointestinal stromal tumours and leads the 7th WP “Minimally Invasive Therapy”.

Dominika Adams

AdamsD_pic_black and whiteDr. rer. nat. Dominika Adams completed her doctorate studies at the Institute of Physical Chemistry at the University of Muenster as a member of the Graduate School of Chemistry (GSC-MS). Her research focused on electrical and structural characterization of materials using impedance spectroscopy and nuclear magnetic resonance. Her professional experience includes working as a postdoctoral researcher at Philipps-University Marburg and as an applications scientist at Veeco GmbH. Mrs. Adams gained her first experience of working European Commission Framework projects in Marburg. She was involved in the HI-CONDOLEC project supported by the European Commission as a part of the FP6 for Research and Technological Development ( At the beginning of 2013 she completed professional training in project management at alfatraining GmbH Bildungszentrum Mannheim. She joined the MITIGATE team in December 2013 undertaking responsibility for project management at the Ruprecht Karl University of Heidelberg.

Arman Smakic

Smakic BW

Arman Smakic finished his medical studies at the University of Heidelberg in November 2013. In the last two years of his medical training he participated in the eu-project euheart as a doctoral candidate at the Institute of Radiology- University Clinics Heidelberg.

At the beginning of 2014 he joined the Department of Clinical Radiology and Nuclear Medicine, University Medical Centre Mannheim and the MITIGATE project. As a member of the 7th WP he will investigate new minimally-invasive treatment concepts for gastrointestinal stromal tumours.


Radiochemistry and Molecular Imaging

Role and Contribution

The task of “Molecular Imaging and Radiochemistry-Team” within the MITIGATE consortium is the development of radioactive labelled biomolecules which comprise a high affinity to cell surface structures displayed on gastrointestinal stromal tumours (GIST. The aim of the project is on the one hand to provide agents for quantitative detection of tumours and their metastases using positron emission tomography (PET), a non-invasive molecular imaging tool, and on the other hand to enable the targeted destruction of cancer cells without affecting healthy tissues. The selected radioactive nuclide determines the application of the radiolabelled biomolecule: Positron-emitting nuclides like Fluoride-18 or Gallium-68 comprise a short half-life of 1-2 hours which facilitates PET-imaging without harming any cells, both tumorigenic and healthy ones. Nuclides used for therapy purposes possess an elongated half-life (few days). Based on their emitted radiation range and intensity cancer cells can be destroyed effectively. Adverse effects towards healthy tissue can be obviated by the specificity of the used biomolecules (vehicles) which only target cell surface structures typically displayed on tumour cells. Biomolecules comprising the possibility to be labelled either with a diagnostic or a therapeutic radioactive nuclide are termed as “Theranostics” (therapeutics + diagnostics) and will be developed within the framework of the MITIGATE consortium aiming “from bench to bedside”.


Björn Wängler


Prof. Dr. Wängler studied Chemistry and Mathematics at the Johannes Gutenberg-University Mainz. His Master-Thesis dealt with the synthesis and evaluation of potential PET-Radiopharmaceuticals for the evaluation of the MGMT-status of tumors in vivo. In the following PhD-Thesis (2002-2004) he worked on new methods for the early diagnosis of diabetes mellitus. His thesis entitled “Synthesis, 11C- and 18F-Labeling and evaluation of  Repaglinide-derivatives for the quantification of the pancreatic β-cell-mass in vivo with PET“ was honoured with the Award of the International Isotope Society – Central European Division (IIS-CED). After a one-year Postdoc  at the German Cancer Research Center, Heidelberg, in the Department of Medical Physics in Radiology in the group of Prof. Dr. Fabian Kiessling, he started a group leader position at the Geman Cancer Research Center in the Department of Radiopharmaceutical Chemistry. 2006-2011 he was Head of Research in the department of Nuclear Medicine of the Hospital of the University Munich. 12/2010 he received his postdoctoral degree (facultas docendi/ venia legendi) in Experimental Nuclear Medicine. 07/2010 he was offered a position as professor of molecular Imaging and Radiochemistry at the University Heidelberg, 04/2011 he was offered a position as associate professor at the Ludwig-Maximilians-University in Munich. He accepted the professorship at the Medical Faculty Mannheim of the University Heidelberg 06/2011 and started the appointment in fall 2011.

In the MITIGATE Project he is responsible for the development of new theranostics and project-leader of  WP4: “Target Analysis and Molecular Probe Design”.

Sabrina Niedermoser


Sabrina Niedermoser studied pharmacology at Leopold-Franzens-University of Innsbruck. Her diploma thesis dealt with the synthesis of new aldose-reductase inhibitors containing either a methylene aminooxy hexanoic acid or a nitrophenol-substructure and the biological examination of these substances in vitro. Upon receipt of her Austrian Pharmacist’s Diploma (Staatliches Apothekerdiplom) she practiced her profession at a pharmacy. In 2009 she initiated her graduate thesis at the Department of Nuclear Medicine at the University of Munich Hospital (LMU), supervised by Prof. Dr. Björn Wängler. She synthesized new hydrophilic [18F]SiFA (Silicium-based Fluoride-Acceptor) modified Octreotate derivatives, applied an optimized Kit-like Fluoride-18 labelling strategy, and examined the chemical and biological impact of her radiolabelled peptides in vitro and in in vivo studies. In 2012 she continued her research at the IKRN, Department for Molecular Imaging and Radiochemistry at the Medical Faculty Mannheim of Heidelberg University. Her research work, performed during her graduate thesis, was honoured 2013 in Vancouver at the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) by awrding to her the „SNMMI Radiopharmaceutical Sciences Council Young Investigator Award, 1st Prize“.

Martin Prause

Martin PrauseMartin Prause studied chemistry at Technical University of Munich with focus on organic and macromolecular chemistry. In his Master’s thesis in the group of Pharmaceutical Radiochemistry at Rechts der Isar Hospital, he worked on the synthesis and in vitro evaluation of novel sterically constricted small molecule inhibitors of prostate specific membrane antigene. In 2014 he joined the Mitigate Project for his doctoral thesis focusing on the synthesis and evaluation of specific 18F labelled radiotracers for gastrointestinal stromal tumors.

Department of Computer Assisted Clinical Medicine

Role and Contribution

The Department of Computer Assisted Clinical Medicine at the University of Heidelberg (UHEI) has many years of experience (since 1985) in developing new methods and techniques for magnetic resonance imaging (MRI) with strong focus on medical technology using MR imaging and spectroscopy for modern treatment planning and monitoring.

The contribution of the CKM/UHEI to the MITIGATE project is organized in following tasks:

  • The 23Na MRI technique will be integrated for the non-invasive quantification of tissue sodium concentration helping to assess cytotoxicity and cell death in GIST tumours caused by breakdown of the sodium-potassium-pump
  • New MR measuring sequences for X-nuclei MRI will be developed and optimised for fast MR measurements in order to provide high contrast and high resolution X-nuclei MR images of soft tissue in the abdomen
  • The development of special RF resonator concepts will help for multinuclear signal detection (hydrogen and sodium) in various abdominal regions with maximised sensitivity,
  • The X-nuclei MR data will be reconstructed, scaled and fusioned with further imaging modalities using OSIRIX.
  • The time-resolved 4D volume and dual-energy CT perfusion will be integrated into the interventional platform for quantification of tumour vascularity and a real-time navigation during treatment will be possible.


Lothar Schad

L SchadProf. Dr. rer. nat. Lothar Schad received his Ph.D. in Nuclear Physics from the University of Heidelberg, Germany, in 1983. In 1984 he was postdoctoral fellow of the Max PlanckInstitute of Nuclear Physics, Heidelberg. From 1985 to 2007 he served as a research assistant in Medical Physics at the German Cancer Research Centre, Heidelberg.

From 1990 to 1995 he was Heisenberg scholarship holder of the German Scientific Community. In 1991 he received the Venia Legendi for Medical Physics at the University of Heidelberg. Since 2007 he has been the Chair and Director of the Institute of Computer Assisted Clinical Medicine at the Medical Faculty Mannheim of the Heidelberg University. Since 2004 he is Editor-in-Chief of “Zeitschrift für Medizinische Physik”. His research interest lies in MRI and its applications to diagnostics and therapy.

Frank Zöllner

F_ZoellnerDr. Ing. Frank G. Zöllner received the diploma and a PhD degree (Dr.-Ing.) in computer science from the University of Bielefeld, Germany, in 2001 and 2004, respectively. He joined the Applied Computer Science group in 2001 and worked towards his PhD within the bioinformatics graduate program (Graduiertenkolleg ‘Bioinformatik’) until 2004. From 2004 until 2006 he worked as a post-doctoral researcher in the BMBF project ALPIC. From 2006 until 2007 he was a researcher at the Section of Radiology, Institute for Surgical Sciences, Haukeland University Hospital and the Neuroinformatics and Image Analysis Group, Section for Physiology, Department of Biomedicine at the University of Bergen, Norway. Currently, he holds a 10% research position at the Section of Radiology, Institute for Surgical Sciences, Haukeland University Hospital. He is an associate member of the Bergen Image Processing Group and the MedViz Network. In 2008 Dr. Zöllner joined the Chair of Computer Assisted Clinical Medicine as a post-doctoral researcher. He leads the junior research group MRI and Pattern Recognition. His research interests lie in the fields of pattern recognition, image processing as well as bioinformatics. In particular, he is interested in applying computational methods from pattern recognition, image analysis, or bioinformatics to the fields of molecular imaging and medical image analysis. Currently, he works on magnetic resonance imaging (MRI) of the human kidney for diagnostics of renal disease.

Dr. Zöllner is a member of the IEEE Computer Society and the European Society for Magnetic Resonance in Medicine and Biology (ESMRMB).

Simon Konstandin

Dr. rer. nat. Simon Konstandin received his diploma (2008) and PhD (Dr. reS_Konstandinr. nat., 2012) degree in physics at Heidelberg University, Germany. Since 2012 he has been working as a postdoctoral researcher at the Department of Computer Assisted Clinical Medicine in Mannheim,

Germany. He leads the group “Multinuclear NMR”, which is mainly focused on sequence development for X-nuclei magnetic resonance imaging with ultra-short echo times and high SNR efficiency.

Nadia Paschke

NadiaPaschkeNadia Paschke finished her electrical engineering studies at the Karlsruhe Institute of Technology (KIT) in May 2014 (M.Sc.). In her Master’s thesis written at the Department of Biomedical Engineering, King’s College London she did research on respiratory motion compensated reconstruction approaches of high-resolution MR images.  In 2014 she joined the Mitigate Project for her doctoral thesis investigating the 23Na MRI technique for non-invasive quantification of tissue sodium concentration.

Medical Radiation Physics (MRP) / Radiation Protection

Role and Contribution

The “Medical Radiation Physics / Radiation Protection” (MRP) group is focused on the development of personalized medicine in radiation therapy using molecular imaging. Research activities lie on the interface of “Ionising Radiation Effects” and “Imaging”. Individual optimization of radiation effects in cancer therapy is performed by the development of measurement protocols for imaging techniques, by the development of methods, which selectively work out the key information contained in the measurement data for the therapy, and by optimising the radiation or radionuclide therapy itself based on the results of the imaging procedures and radiobiological findings.

The group contributes to WP4, WP5 and WP6. Therein, the assessment and prediction of the biodistribution of new compounds for endoradiotherapy will be performed. As endoradiopharmaceuticals also accumulate partly in non-target tissues, this accumulation in metabolising organs limits the dose. Therefore, the dose must be accurately predicted for all relevant tissues. This can be estimated from PET measurements of the corresponding targeting vector labelled with a positron-emitting radionuclide. To optimize individual biodistribution (for animal models and humans) physiologically based pharmacokinetic (PBPK) modelling and simulation will be used.

Absorbed dose calculations will be performed for treatment planning and medical physics knowledge will be provided to all partners.


Gerhard Glatting

Glatting Gerhard_new1988 Diploma, Physics, Ulm University

Diploma thesis (“Theoretische Untersuchungen zur Temperaturabhängigkeit optischer Linienbreiten in Gläsern” [Theoretical investigation of the temperature dependence of optical linewidths in the glassy state])

1993 PhD Institute für Theoretische Physik, Ulm (“Zur Theorie des gummielastischen Verhaltens polymerer Netzwerke” [Theory of the rubber-elastic behaviour of polymer networks])

1990-1991 Additional study programme Mathematical Economics

1993- 2011 Scientist, Nuclear Medicine Clinic, Ulm University

1994-1996 Postgraduate study (distance learning) “Medical Physics and Engineering” Kaiserslautern Technical University

1997 Board certification “Medical Physics” (DGMP)

1999 Technical qualification in radiation protection (medical physics expert)

Accreditation for medical physics teaching (DGMP) in nuclear medicine

1998-1999 Open course studies Applied Computer Science, Open University Hagen

2005 Habilitation/assistant professor for Medical Physics (“Zur Bildrekonstruktion in der Positronen-Emissions-Tomographie“ [Image reconstruction in Positron Emission Tomography])

2007 Associate Professor, Ulm University

2011 Full professor in Medical Radiation Physics / Radiation Protection, Medical Faculty Mannheim, Heidelberg University

Since 2002 Co-Editor „Zeitschrift für Medizinische Physik“ (IF=1.407, 2012)

Since 2013 Editorial Board Member „EJNMMI Physics“

2008 Science Award of the DGMP 2008 “Herausragende Wissenschaftliche Leistungen auf dem Gebiet der Medizinischen Physik“


Luis David Jiménez

Luis David JiménezLuis David Jiménez studied electronic engineering at the Universidad Pontificia Bolivariana (Colombia). He also finished master studies in engineering (Universidad EAFIT – Colombia, 2013) and in Medical Physics (Ruprecht-Karls-Universität Heidelberg – Germany, 2015). For his medical physics master’s thesis he researched the application of cone beam CT images in treatment planning for intraoperative radiotherapy (Universitätsmedizin Mannheim). Since January 2016 he is developing physiologically-based pharmacokinetic (PBPK) models in the Medical Radiation Physics/Radiation Protection research group at Ruprecht-Karls-Universität Heidelberg where he works as a doctoral student.

Department of Radiation Oncology


Frederik Wenz

Wenz_BWProfessor and Chairman, Department of Radiation Oncology, University Medical Centre Mannheim, University of Heidelberg, Vice Chief Medical Officer, University Medical Center Mannheim, Head, Interdisciplinary Cancer Center, University Medical Center Mannheim

Dr. Wenz received his MD degree from the University of Heidelberg in 1992 after studies in medicine and physics in Heidelberg, Birmingham, San Antonio and Chicago. He performed the experimental work for his M.D. thesis at the German Cancer Research Center in Heidelberg, where he also started his internship in diagnostic radiology (Prof. G. van Kaick). He moved to the University of Heidelberg for a residency in radiation oncology (Prof. M. Wannenmacher). After performing a fellowship in cancer biology at the Harvard School of Public Health, Boston (Prof. J.B. Little), he was promoted to attending at Heidelberg University. In 2000 he became professor and chairman in the department of radiation oncology at the University Medical Center Mannheim, University of Heidelberg.

Dr. Wenz has published more than 300 peer review journal papers and edited 4 text books. He served as an editorial board member in several journals. The clinical specialties are breast and prostate cancer, while the research interests are focussed on novel technologies like intensity modulated radiotherapy (IMRT), image guided radiotherapy (IGRT), stereotactic ablative radiotherapy (SABR), intraoperative radiotherapy (IORT) and radioprotective gene-therapeutic approaches


Daniel Buergy

BuergyDaniel Buergy studied medicine at the Medical Faculty Heidelberg, and the Medical Faculty Mannheim at Heidelberg University. He received his license to practise medicine in November 2008. In 2009 he completed a Master’s thesis on factors influencing work satisfaction in senior management staff members of German companies, as part of a master’s program (2006-2009) in Healthcare Management (Heidelberg University in cooperation with SRH University Heidelberg).

In his medical thesis he worked on new diagnostic and prognostic markers in thyroid carcinoma and colorectal cancer. The work was supervised by Professor Dr. Allgayer, MD, PhD and honored with the research award of the Oncological Board Mannheim (2010, summa cum laude).

Dr. Buergy works as a physician in the Department of Radiation Oncology and has clinical experience in internal medicine and anaesthesiology. His research interests include technical approaches to low-dose rate Brachytherapy, toxicity and quality of life after Brachytherapy or re-irradiation with external beam radiation therapy. In the MITIGATE Project, he is investigating therapeutic approaches targeted at tyrosine kinase inhibitor (TKI)-resistant tumours.